Previous 10 | Next 10 |
Curis Announces Three Presentations at ASH PR Newswire LEXINGTON, Mass. , Dec. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, to...
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma PR Newswire LEXINGTON, Mass. , Dec. 5, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orall...
Curis, Inc. (NASDAQ: CRIS) is one of today's top gainers. The company's shares have moved 6.09% on the day to $4.18. Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage dru...
2023-11-17 10:00:08 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Curis, Emergen...
2023-11-02 14:32:09 ET Curis, Inc. (CRIS) Q3 2023 Earnings Conference Call November 02, 2023 08:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Conference Call Participants Yale ...
2023-11-02 08:05:49 ET More on Curis Seeking Alpha’s Quant Rating on Curis Historical earnings data for Curis Financial information for Curis For further details see: Curis GAAP EPS of -$2.13 beats by $0.23, revenue of $1.8M misses by $0.83M
Curis Provides Third Quarter 2023 Business Update PR Newswire Continued progress on the development of emavusertib Strong balance sheet with $68.5 million in cash and investments; cash runway into 2025 Management to host conference call today at 8:30 a.m....
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023
2023-11-01 14:00:24 ET More on Curis Curis, Inc. (CRIS) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Curis Historical earnings data for Curis Financial information for Curis For further details see: Curis Q3 2023 Earning...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...